Oral vs Vaginal Progesterone for HRT: What the Labels and the 2026 Evidence Actually Say
Match the route, product, and next care question
Find My HRT Path organizes symptoms, medication route, uterus history, insurance, state, and questions for a menopause-care visit. It does not replace your prescription label, pharmacist, or clinician.
For oral vs vaginal progesterone for HRT, oral micronized progesterone is the only micronized-progesterone option with a U.S. FDA label for a defined menopausal endometrial-protection use. It is the clearest starting point when tolerated. Vaginal progesterone is off-label for this U.S. use; May 2026 UK guidance says oral-equivalent doses and durations should ordinarily be used.
That last part is what almost nobody has updated. The 45 mg vaginal dose you'll still see quoted traces back to a 2016 review. In 2021, a randomized trial tested that exact regimen with oral estradiol for a median 4.8 years and found it did not fully oppose estrogen's effect on the uterine lining.
We'll show you both, side by side, with the numbers. And then we'll show you something about where that 2016 recommendation came from that we haven't seen assembled anywhere else.
Is vaginal progesterone best for you—or not?
Answer capsule: Vaginal progesterone is not the default winner. It is a route to discuss when oral effects are genuinely intolerable and a prescriber can define the product, dose, and follow-up. It is a poor shortcut when the real goal is to use less progesterone, avoid bleeding evaluation, or preserve an oral sleep benefit without knowing the trade.
Vaginal progesterone may be worth asking about if: oral progesterone makes you dizzy, foggy, low, or bloated; you've already tried the labeled bedtime timing and the problem remains; and your prescriber will choose the exact product, write an evidence-based dose, and give you a bleeding and follow-up plan.
It's probably not your answer if: oral progesterone is the reason you finally sleep; you're hoping it's cheaper; you're hoping to take less progesterone rather than a clinically adequate amount by a different route; or you have bleeding that hasn't been evaluated.
This page can't decide for you if: you have unexplained bleeding, a hormone-sensitive cancer history, a clotting history, high-dose or unusual estrogen, a complex uterine history, or you're weighing a compounded product. Those need a clinician who can see your whole history.
Peanut allergy changes the product question, not just the route. Brand-name Prometrium contains peanut oil. Generic excipients vary, so check the label for the exact manufacturer in your bottle rather than assuming every capsule is the same.
How do oral and vaginal progesterone compare?
Answer capsule: Oral progesterone has the strongest U.S. label and endometrial evidence, while “vaginal progesterone” can mean three materially different things: the oral capsule inserted off-label, a purpose-made insert or gel labeled for assisted reproduction or amenorrhea rather than menopause, or a compounded preparation. The label, dose evidence, systemic effects, and price are not interchangeable across those options.
| Option | U.S. FDA status for menopausal endometrial protection | What the evidence or current guidance supports | Sedation / sleep evidence | U.S. price snapshot, August 7, 2026 | Main tradeoff |
|---|---|---|---|---|---|
| Oral micronized progesterone capsule, swallowed | Yes, in a narrow labeled scenario: nonhysterectomized postmenopausal women receiving conjugated estrogen tablets | Label: 200 mg at bedtime for 12 days per 28-day cycle. Continuous 100 mg nightly is common guideline-based off-label practice, not in the U.S. label. | Best documented. In the label trial, dizziness was reported by 15% on the 200 mg regimen versus 9% on placebo. | GoodRx displayed $18.96 for 30 generic 100 mg capsules; Drugs.com displayed $17.54–$24.50 for 30 generic 200 mg capsules | Grogginess or dizziness; brand Prometrium contains peanut oil |
| Oral capsule inserted vaginally | No | May 2026 British Menopause Society guidance says this can be considered exceptionally for oral intolerance, using the same doses and durations as oral, but notes there are no published absorption-kinetic data for oral capsules used this way | Not established for this exact use. Do not assume the sleep benefit disappears or that systemic effects are predictably lower. | Same prescription product price as the oral capsule | Cheapest route change, weakest product-specific pharmacokinetic evidence |
| Purpose-made 100 mg vaginal insert: Endometrin or generic | FDA-approved for assisted reproductive technology, not menopause HRT | Has product-specific vaginal pharmacology, but no U.S.-labeled menopause regimen. A prescriber would be extrapolating off-label. | Menopause route-switch effects have not been established | GoodRx displayed $91.03 for 21 generic inserts; the brand page displayed an average retail price around $320.50 for the common version | Cost, discharge or residue, and an indication mismatch |
| Crinone vaginal gel: 45 mg or 90 mg per applicator | Crinone 8% is approved for assisted reproductive technology; Crinone 4% for secondary amenorrhea. Neither is approved for menopausal endometrial protection. | The exact 45 mg for 10 days/month regimen failed to fully oppose oral estradiol 1 mg/day in the ELITE analysis. Crinone's 45 mg and 90 mg strengths are not direct substitutes for 100 mg and 200 mg oral doses. | Serum exposure is lower than intramuscular progesterone in label pharmacokinetic studies, but menopause sleep outcomes were not studied | GoodRx displayed $129.84 for six 4% applicators and $489.37 for fifteen 8% applicators | Cost, leakage or residue, and no established U.S. menopause dose |
| Compounded vaginal progesterone | Finished product is not FDA-approved | Potency, purity, formulation, and evidence depend on the specific preparation. It must not be treated as equivalent to an FDA-approved capsule, insert, or gel. | Product-specific evidence usually unavailable | Must be confirmed with the dispensing pharmacy; no unlabeled estimate belongs here | Variability and the absence of an FDA-reviewed finished product |
| 52 mg levonorgestrel IUD | No U.S. HRT indication; U.S. labeling covers contraception and heavy menstrual bleeding | May 2026 BMS guidance says a 52 mg system provides adequate endometrial protection with estrogen therapy for up to five years; this use remains off-label in the U.S. | Does not reproduce oral progesterone's sedating exposure | Device and placement cost must be confirmed with the clinician and insurer | Insertion, early irregular bleeding, and no oral sleep effect |
Price figures are the exact quantities displayed by GoodRx or Drugs.com on August 7, 2026—not universal pharmacy prices, insurance prices, or promises of a menopause regimen. Prices vary by pharmacy, ZIP, coupon eligibility, stock, and prescribed quantity. Full source links and the arithmetic limits appear in the cost section.
Before you go further: don't stop your progesterone on your own.
If you have a uterus and take systemic estrogen, adequate endometrial protection is not the optional part. For most regimens that means a progestogen; Duavee is a different FDA-approved strategy. Everything here is about changing the plan with a prescriber—not quietly reducing or removing protection.
Oral vs vaginal progesterone for HRT: why is this really four different questions?
Answer capsule: "Vaginal progesterone" is not one thing. It can mean an oral capsule inserted off-label, an FDA-approved vaginal gel or insert whose approval covers fertility or amenorrhea rather than menopause, or a compounded preparation whose finished product is not FDA-approved. Each carries different labeling, evidence, strengths, and price, so a general claim about "the vaginal route" cannot be applied to all three.
Most pages on this topic use two columns: pill versus insert. That's where the confusion starts. It's also why two reasonable clinicians can give you opposite answers and both be right about the thing they're actually describing.
Here's what people mean when they say it:
1. The oral capsule, swallowed. Micronized progesterone—progesterone processed into very small particles to improve oral absorption—sold as Prometrium and as generics. The current Prometrium label covers prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogen tablets.
2. The same oral capsule, inserted. Physically possible. Used in specialist practice. Off-label. And, as you'll see, the route for which May 2026 BMS guidance says there are no published absorption-kinetic data for oral capsules used vaginally.
3. A purpose-made vaginal product. Crinone gel and Endometrin inserts are FDA-approved—but read what they're approved for. Endometrin and its generics are approved for progesterone support in assisted reproductive technology. Crinone 8% is approved for progesterone supplementation or replacement in assisted reproductive technology. Crinone 4% is approved for secondary amenorrhea. None carries a U.S. FDA indication for endometrial protection during menopausal HRT.
4. A compounded vaginal preparation. A pharmacy makes it to a prescriber's formula. The finished product is not FDA-approved. Compounded and FDA-approved products are not equivalent, and nothing on this page should be read as saying otherwise.
What "FDA-approved" actually attaches to
This is the most useful idea on the page, and it takes ten seconds to learn.
FDA approval doesn't attach to a molecule by itself. It attaches to a product, formulation, route, dose, population, and indication.
So "progesterone is FDA-approved" is an unfinished sentence. Prometrium taken orally for its labeled endometrial-hyperplasia indication—approved. A progesterone vaginal insert used to protect the endometrium during menopause HRT—not approved for that indication.
Progesterone may appear on each label. The regulatory status can still be completely different.
Once you see that, a lot of confident claims on the internet fall apart.
One more thing people mix up
Vaginal estrogen and vaginal progesterone are not the same conversation. If you use a current low-dose vaginal estrogen product for dryness or painful sex and someone told you that means you automatically need progesterone, that's a different question. The Menopause Society’s 2022 hormone-therapy position statement generally does not call for adding a progestogen solely because of low-dose local vaginal estrogen. Start with our separate guide to vaginal estrogen vs systemic estrogen.
This page assumes you're on systemic estrogen—a patch, gel, spray, pill, or injection intended to produce body-wide treatment effects.
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
Affiliate disclosure: The HRT Index may earn a commission if you use certain provider links. That does not change the evidence standards or the order of the conclusions on this page.
Why do you need progesterone with estrogen in the first place?
Answer capsule: Estrogen makes the lining of the uterus grow. Without enough progestogen to oppose it, that lining can thicken abnormally, and abnormal thickening can progress to cancer. In the FDA label's 36-month randomized study, endometrial hyperplasia occurred in 64% of women assigned conjugated estrogens alone versus 6% of women who also received progesterone 200 mg for 12 days per cycle.
That trial sits inside the current U.S. prescribing information for Prometrium. Here it is:
| Treatment group | Endometrial hyperplasia over 3 years |
|---|---|
| Conjugated estrogens 0.625 mg + progesterone 200 mg for 12 days/cycle | 6% |
| Conjugated estrogens 0.625 mg alone | 64% |
| Placebo | 3% |
Sixty-four percent versus six. That's not a decorative precaution. That's the reason adequate opposition exists in the prescription.
Which is why the answer to “can I simply remove the endometrial-protection part?” is no if you have a uterus and continue systemic estrogen—and why the honest version of this page has to be a little disappointing in places.
Who this applies to, and the exceptions people get wrong
- You have a uterus and take systemic estrogen → you generally need adequate progestogen or another clinician-selected endometrial-protection strategy. This page is for you.
- You've had a full hysterectomy → you generally don't need progestogen for endometrial protection. Ask about the plan if the hysterectomy was for severe endometriosis, because guidance differs and the evidence is limited.
- You've had an endometrial ablation → an ablation treats the lining but does not remove the uterus. May 2026 BMS guidance says combined HRT regimens should still be used after ablation. You are not in the "no uterus" group.
- You've had a partial or supracervical hysterectomy → residual endometrial tissue may remain. BMS guidance describes sequential progestogen for up to three months as a common way clinicians assess whether residual tissue appears to be present.
- You only use low-dose vaginal estrogen → different question. See above.
Two of those five come up constantly and are almost never spelled out. If you've had an ablation and you've been filing yourself under "no uterus," raise it with your prescriber.
Why does oral progesterone make you feel like that?
Answer capsule: Swallowed progesterone undergoes first-pass metabolism, producing neuroactive metabolites that can cause sedation, dizziness, and the “drunk” feeling some women describe. The current Prometrium label directs bedtime dosing, documents dizziness in 15% of women on the 200 mg cyclical regimen versus 9% on placebo, and warns that transient dizziness and drowsiness can occur.
If mornings have felt like wading through wet sand, you weren't imagining it and you weren't being dramatic.
Here's the part almost nobody publishes: the placebo column. Every article lists progesterone's side effects. Very few show what women in the placebo arm reported in the same trial. Without that, every headache or sore joint gets blamed on the capsule whether the comparison supports it or not.
From the FDA label—a three-year placebo-controlled trial in 875 postmenopausal women. The table compares the subgroup receiving progesterone 200 mg for 12 days a month plus conjugated estrogens 0.625 mg (n=178) with placebo (n=174):
| Reported effect | Progesterone + estrogen | Placebo |
|---|---|---|
| Headache | 31% | 27% |
| Breast tenderness | 27% | 6% |
| Joint pain | 20% | 29% |
| Depression | 19% | 12% |
| Dizziness | 15% | 9% |
| Abdominal bloating | 12% | 5% |
| Hot flashes | 11% | 35% |
| Vaginal discharge | 10% | 3% |
| Nausea or vomiting | 8% | 7% |
| Night sweats | 7% | 17% |
A separate, smaller label trial using 400 mg daily for secondary amenorrhea reported dizziness in 24% versus 4% on placebo. That is a different population, dose, and study—not a clean dose-response comparison—but it confirms dizziness is not imaginary.
Spend two minutes with the table and you learn things prose can't teach:
- Headache and nausea sat close to placebo in this trial. That doesn't rule out an individual reaction, but it changes how confidently the capsule deserves the blame.
- Dizziness and bloating showed a clearer difference.
- Breast tenderness was one of the largest gaps—27% versus 6%.
- Joint pain was reported more often on placebo. Before you assign every new ache to progesterone, know what the controlled comparison showed.
The sentence in the label that women recognize instantly
In its postmarketing section, the current label describes a cluster reported during initial therapy: extreme dizziness or drowsiness, blurred vision, slurred speech, difficulty walking, loss of consciousness, vertigo, confusion, disorientation, feeling drunk, and shortness of breath.
Feeling drunk. That phrase is in the prescribing information.
It's also the exact phrase women use in appointments where they're worried they'll sound like they're exaggerating. You're not. It's on the label. Bring the label language if you need it.
Try the free fixes first
Before you change route, buy a more expensive product, or accept a new prescription, check the basics. We'd genuinely rather this page saved you a purchase than sold you one.
- Take it at bedtime exactly as directed. The label directs bedtime dosing because transient dizziness and drowsiness can occur. Do not drive or operate machinery after taking it until you know how it affects you.
- Check the food instructions for your exact product. The Prometrium label says food increases progesterone bioavailability at the 200 mg dose. Do not deliberately switch between fed and fasted dosing to chase a different effect; ask the prescriber or pharmacist how they want you to take your product.
- Ask whether the progesterone plan was set against the estrogen dose. May 2026 BMS guidance says the progestogen dose should be proportionate to the estrogen dose. More on that below.
- Check the manufacturer and inactive ingredients. Brand Prometrium contains peanut oil; generic formulations can differ.
You do not have to endure disabling dizziness for an arbitrary number of months to prove you tried hard enough. Severe symptoms, falls, fainting, breathing trouble, or neurological symptoms need prompt clinical advice rather than a patience test.
The honest limitation, up front
Here's the part you may not want to read.
Most of the strongest evidence that micronized progesterone reduces endometrial hyperplasia risk is evidence about the oral route. If you came hoping to learn that every vaginal product is just as protective at a lower dose with fewer side effects, that isn't what the current data shows. One widely repeated low-dose vaginal regimen was tested, and it came up short.
That doesn't make vaginal use wrong. It makes the product, dose, estrogen exposure, and follow-up plan matter more, not less. Current UK guidance treats an oral-equivalent, clinician-directed vaginal regimen as an option for oral intolerance—not a shortcut to less progesterone.
That's a real answer. It's just narrower than the internet is selling.
Does vaginal progesterone actually reduce the risk of endometrial hyperplasia?
Answer capsule: It can, but the product and dose determine whether the evidence applies. Vaginal delivery can target the uterus efficiently, yet the low-dose regimen promoted in a 2016 review—45 mg gel for 10 days a month—was later tested with oral estradiol and did not fully oppose its endometrial effect. May 2026 BMS guidance now says vaginal progesterone used off-label for HRT should ordinarily follow oral-equivalent doses and durations.
This is the section the rest of the internet is missing. Three rows.
The dose reversal, in order
| Year | Source | What it said about vaginal progesterone |
|---|---|---|
| 2016 | Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016;19(4):316–328. | Vaginal micronized progesterone may provide protection at 4% gel, 45 mg/day for at least 10 days a month, or 100 mg every other day, for up to 3–5 years—off-label. The review also acknowledged that evidence was insufficient to define optimal vaginal practice. |
| 2021 | Sriprasert I, Mert M, Mack WJ, Hodis HN, Shoupe D. Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women. Maturitas 2021;154:13–19. Randomized, double-blind, placebo-controlled ELITE analysis; median follow-up 4.8 years, up to 80 months. | Tested oral estradiol 1 mg/day plus vaginal progesterone gel 45 mg/day for 10 days each month. The combination group developed progressively greater endometrial thickness (p<0.001), underwent more biopsies (RR 2.11, 95% CI 1.65–2.69), and had a higher hyperplasia signal (RR 15.9, 95% CI 0.97–260.7) than placebo. The authors concluded that regimen was insufficient to fully oppose oral estradiol 1 mg/day. |
| 2026 | British Menopause Society, Tool for Clinicians: Progestogens and Endometrial Protection, May 2026. UK professional guidance. | When vaginal progesterone is used off-label because oral intake causes side effects, it should ordinarily be given at similar doses and durations to oral progesterone used in HRT. The document still says evidence is limited and more adequately powered studies are needed. |
Plainly: the later trial tested the exact 45 mg for 10 days regimen that the 2016 review had said might be protective, and it didn't hold against oral estradiol 1 mg/day. Pages still repeating 45 mg without the 2021 result are giving you half the evidence chain.
Read the sources yourself: the 2016 systematic review, the 2021 ELITE endometrial analysis, and the May 2026 BMS clinician tool.
Something we noticed that we haven't seen anyone else assemble
We read the disclosure sections, not just the abstracts.
The 2016 review states that the authors participated in a German-speaking expert board funded by Dr. Kade/Besins Pharma, and that the board meeting was funded by the company. The 2024 follow-up review discloses that lead author Petra Stute received honoraria for consultancies and/or presentations from Besins Healthcare, Theramex, and Gedeon Richter. Besins markets micronized progesterone products outside the United States.
We want to be careful here, because this is easy to misuse.
This is not an accusation, and it is not a reason to discard either review. Disclosed industry relationships are common in a small specialty, and publication of the relationship is the disclosure system doing its job.
But it is part of the provenance of the 45 mg recommendation. A recommendation that broadened off-label vaginal use arose from an industry-supported expert process, carried an explicit “insufficient data” limitation, and was later challenged by a randomized trial of the exact regimen. That is material context when a clinic blog repeats “45 mg” as though it were settled.
The same group's 2024 systematic review is more cautious. It says FDA endometrial-safety criteria were met for only some progestogen formulations and that study quality varied—especially relevant when an off-label formulation or regimen is being considered.
That is the original asset on this page: not a score and not a scandal, but a traceable evidence chain from recommendation, to trial, to updated guidance, with the disclosures left attached.
The honest limits on the 2021 finding
We're not going to overstate this, because overstating it would make us as unreliable as the pages we're correcting.
The hyperplasia relative risk of 15.9 has a confidence interval running from 0.97 to 260.7. A range that wide means the event estimate is imprecise. The progressive thickness finding and doubled biopsy rate are more statistically stable signals, but this was an endometrial analysis within a larger trial, not a trial designed to compare every vaginal product and oral-equivalent regimen.
The finding applies to oral estradiol 1 mg/day plus Crinone 4% gel delivering 45 mg/day for 10 days each month. It does not prove that every vaginal regimen fails. It proves that “vaginal progesterone works” is not a dose-free statement.
The British Menopause Society is also a UK body. It is not the FDA, and its available vaginal products differ from U.S. products. We cite it because it is the most current professional guidance we found that answers this exact route-and-dose question directly, and we label it as UK guidance every time it carries the conclusion.
Why vaginal should work—the mechanism is real
None of the above means the vaginal route is biologically implausible. The uterine-targeting mechanism is real.
Vaginal administration can produce lower serum concentrations while achieving high concentrations in uterine tissue—the “first uterine pass” effect. That is one reason specialists consider the route when systemic side effects make oral treatment hard to tolerate. Research on uterine targeting predates the current menopause debate by decades, and the Crinone label contains product-specific vaginal pharmacokinetic data.
Lower in the blood can coexist with meaningful delivery to the uterus. Exactly what you'd want if systemic exposure is the problem.
The question was never whether vaginal delivery can reach the uterus. It's whether a specific product, strength, schedule, and estrogen exposure delivers enough protection over time.
What the reassuring studies actually measured
Two studies get cited frequently as reassurance. Both are worth knowing—including their gaps.
- A 12-month randomized trial of 100 women, all using a 50 microgram estradiol patch, compared oral 100 mg and 200 mg with vaginal 100 mg and 200 mg on days 14–25. It found no significant difference in endometrial thickness between groups, but assessed thickness by ultrasound rather than long-term histology.
- A six-month study using Crinone 4% in menopausal women included cyclical and twice-weekly schedules. Women with abnormal bleeding were biopsied, and no hyperplasia was reported during that short follow-up.
Neither study answers the question the way a long, adequately powered biopsy-based menopause trial would.
That's not a reason to reject the vaginal route. It's a reason to stop treating “vaginal” as a dose, a product, and an outcome all at once.
You now know it can work. The next question is: at what dose, with which product, for you?
Your answer shifts with your estrogen type and dose, whether you're on a cyclical or continuous schedule, your uterus history, your bleeding pattern, and what vaginal product is actually available. → Map your situation with The HRT Index's Find My HRT Path tool Free. About 90 seconds. No email needed. It matches your situation to a care route and flags when online care isn't the right starting point.
What's the right vaginal progesterone dose for HRT?
Answer capsule: No U.S. FDA-approved vaginal progesterone dose exists for menopausal endometrial protection. May 2026 BMS guidance says that when vaginal progesterone is used off-label for oral intolerance, the dose and duration should ordinarily match oral HRT regimens—typically 200 mg for 12 days per cycle or 100 mg daily. That guidance does not turn U.S. fertility inserts or gels into interchangeable HRT products.
Some pages won't print a number here. They'll say it's up to your doctor and leave you with nothing to bring to the appointment.
We think that's a mistake. Professional guidance publishes reference doses. You're allowed to know what it says. Knowing a number is not the same as prescribing it to yourself, and the U.S. product-strength mismatch means the prescriber still has real work to do.
Here's the current UK guidance.
The reference doses
| Regimen type | Micronized progesterone reference dose in May 2026 BMS guidance |
|---|---|
| Cyclical or sequential | 200 mg orally for 12 days per cycle |
| Continuous combined | 100 mg orally daily |
| Example with higher-dose estrogen: cyclical | 300 mg for 12 days per month |
| Example with higher-dose estrogen: continuous | 200 mg daily |
| Vaginal use for oral intolerance | Ordinarily the same doses and durations used for oral HRT |
The first two rows are reference HRT doses in UK guidance. The higher-dose rows are examples—not FDA-labeled U.S. doses and not a declaration that every woman using a higher-dose patch needs exactly that amount.
The product-strength problem the dosing table hides
In the UK, the BMS can point to vaginal tablets or pessaries in 100 mg and 200 mg strengths. The U.S. purpose-made products don't line up so neatly:
- Endometrin and its generics: 100 mg vaginal inserts, FDA-approved for assisted reproductive technology—not menopause HRT.
- Crinone 4%: 45 mg per applicator.
- Crinone 8%: 90 mg per applicator.
- Oral micronized progesterone capsules: commonly 100 mg or 200 mg, labeled for oral administration; insertion is off-label.
That is why “same dose as oral” does not mean “pick any vaginal product and match the number on the box.” Formulation, release, vehicle, and labeled use differ. A clinician must choose the product and schedule, not just the milligrams.
The rule almost nobody is told: the progesterone plan depends on the estrogen exposure
May 2026 BMS guidance is explicit that progestogen dose should be proportionate to estrogen dose. It also states that direct data defining the optimal oral or vaginal dose with high-dose estrogen are not available. Its 300 mg cyclical and 200 mg continuous examples are a response to that uncertainty, not proof of a perfect formula.
So hold your own prescription against one question:
Was the progestogen plan chosen in relation to the estrogen route and dose—or were the two prescribed as separate habits?
If you're using a higher-dose estrogen regimen, do not use this article to declare yourself “under-opposed.” Use the guidance to ask for the prescriber's rationale and monitoring plan.
Two more numbers worth carrying in
- At least 12 days matters for oral micronized progesterone in the labeled cyclical regimen. Broader evidence associates fewer than 10 days of progestogen per month in sequential therapy with higher endometrial risk, but that does not make every 10-day regimen adequate—the failed 45 mg gel regimen proves dose still matters.
- Milligram-for-milligram equivalence is not automatic across products. The same number by a different route or formulation does not guarantee the same tissue exposure or protection. That's why the oral-capsule, Endometrin, and Crinone rows stay separate throughout this page.
Is it safe to use Prometrium vaginally if it's off-label?
Answer capsule: “Off-label” means the FDA-approved label does not cover that product-route-indication combination; it does not automatically mean improper care. Using an oral progesterone capsule vaginally for HRT is off-label and recognized in May 2026 UK guidance only as an exceptional option for oral intolerance. The central limitation is specific: no published absorption-kinetic evidence for oral capsules used vaginally.
The phrase “off-label” is doing a lot of damage in this conversation. It makes women think their prescriber must be winging it. That is not what the term means.
But off-label uses do not all stand on equal evidence. Pull out your own prescription and count the layers.
The three-layer off-label ladder
The current U.S. Prometrium label says two narrow things:
- Indication: prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogen tablets.
- Dosage for that indication: 200 mg orally at bedtime for 12 days sequentially per 28-day cycle.
Now compare that with common menopause practice:
| Layer | What you may be doing | In the current U.S. Prometrium label? | Evidence position |
|---|---|---|---|
| 1 | Taking micronized progesterone with an estradiol patch or gel, rather than conjugated estrogen tablets | No | Supported by professional guidance and by randomized menopause trials that used oral micronized progesterone alongside transdermal estradiol, including the four-year KEEPS regimen |
| 2 | Taking 100 mg nightly continuously, rather than 200 mg for 12 days per cycle | No | Standard guideline-based practice, with May 2026 BMS guidance listing 100 mg oral daily for continuous combined HRT |
| 3 | Inserting the oral capsule vaginally | No | Weakest product-specific evidence: May 2026 BMS guidance says no absorption-kinetic evidence is available for oral preparations administered vaginally |
Most U.S. women using an estradiol patch with a nightly 100 mg capsule are already outside the narrow Prometrium label in layers 1 and 2. That does not make their treatment reckless. It means label status and evidence strength have to be discussed separately.
Layer 3 is different because the uncertainty attaches to the exact product used by the exact route. Purpose-made vaginal products have vaginal pharmacokinetic data. The oral oil-filled capsule used vaginally does not.
The 2022 position statement from The Menopause Society supports shared decision-making around hormone-therapy formulation, route, and dose. Route is a legitimate clinical decision. It is also a decision that deserves an answer more specific than “progesterone is progesterone.”
What “no absorption data” means in practice
It means no published study has mapped how the oil-filled oral capsule behaves when used vaginally—how reliably progesterone is released, absorbed into blood, and delivered to endometrial tissue across women and over time.
It may work well in many women. Experienced clinicians are extrapolating from vaginal progesterone biology and purpose-made products, not acting without any rationale. But extrapolation is not product-specific measurement, and you deserve to know which one is holding up your plan.
Ask four things:
- Why this product rather than a purpose-made vaginal product?
- What exact dose and schedule?
- What estrogen route and dose is it opposing?
- What bleeding or follow-up plan tells us the regimen is not working well enough?
The purpose-made products aren't approved for menopause either
Here's the twist that changes the weighting. You might assume the choice is “approved vaginal product versus improvised oral capsule.”
It isn't. No progesterone vaginal insert or gel in the United States carries an FDA indication for endometrial protection during menopausal HRT. Endometrin and its generics are approved for assisted reproductive technology. Crinone 8% is approved for assisted reproductive technology. Crinone 4% is approved for secondary amenorrhea.
So both choices are off-label for the menopause indication. One has product-specific vaginal pharmacology but different strengths and a much higher price. The other is cheap and familiar but has no published absorption kinetics for that route.
That's the actual decision—not “approved versus unsafe.”
How much does vaginal progesterone cost compared with oral?
Answer capsule: The verified August 7, 2026 price gap is large, but it must be compared by product and package—not by invented “monthly” math. Generic oral capsules were displayed at roughly $12–$25 for 30 capsules. A 21-count generic vaginal-insert package was displayed at $91.03 with GoodRx, while Crinone packages were displayed at $129.84 to $489.37. The prescribed menopause quantity remains off-label and must be confirmed.
Prices below were captured on August 7, 2026. They are displayed cash or coupon figures, not guaranteed prices, insurance copays, or first-fill teaser math. Pharmacy, ZIP, stock, coupon eligibility, and prescribed quantity can change the result.
The HRT Index route-and-package price check
| Product and route | Exact displayed quantity | Price captured August 7, 2026 | What the number does—and does not—tell you |
|---|---|---|---|
| Generic progesterone oral capsule, 100 mg | 30 capsules | $18.96 GoodRx price; Drugs.com listed cash pricing from $11.77 | A verified package price. At 100 mg nightly, 30 capsules may equal 30 days, but the prescriber's schedule controls. |
| Generic progesterone oral capsule, 200 mg | 30 capsules | Drugs.com listed $17.54–$24.50 | A verified 30-count range. Do not prorate it to a cycle without the prescribed schedule. |
| Oral capsule inserted vaginally | Same oral capsule package | Same package price as above | Route changes, but the prescription product and package do not. This is the least expensive route switch in the table. |
| Generic progesterone vaginal insert, 100 mg | 21 inserts | $91.03 GoodRx price | FDA-approved generic of Endometrin for assisted reproductive technology, not a U.S.-approved menopause regimen. The required quantity for off-label HRT must be confirmed. |
| Endometrin brand, 100 mg | Common 21-insert version | GoodRx displayed average retail around $320.50 | Brand/package benchmark, not a promised checkout price. |
| Crinone 4%, 45 mg | 6 applicators | $129.84 GoodRx price | This is the 45 mg strength. The 45 mg for 10 days/month regimen failed to fully oppose oral estradiol 1 mg/day in the ELITE analysis. |
| Crinone 8%, 90 mg | 15 applicators | $489.37 GoodRx price | This is 90 mg per applicator, not 100 mg or 200 mg. No U.S.-approved menopause schedule exists. |
| Compounded vaginal progesterone | Pharmacy-specific | Confirm with the dispensing pharmacy | No unlabeled estimate. Formula, quantity, and price are prescription-specific. |
| 52 mg levonorgestrel IUD | One device plus insertion | Confirm with clinician and insurer | Coverage depends on plan, indication coding, network, and placement setting. |
Source: GoodRx oral progesterone pricing, GoodRx Endometrin pricing, GoodRx Crinone pricing, and Drugs.com progesterone price guide.
The part nobody says out loud
At the displayed package prices, purpose-made vaginal products are not a small premium over the capsule. They can be many times more expensive before insurance.
That price gap explains a practice you may already have encountered. When a woman cannot tolerate the oral capsule, some prescribers suggest inserting the same capsule rather than writing for a purpose-made vaginal product.
Usually that's an attempt to keep care accessible. It also means the cheapest route change is the route with the least product-specific absorption evidence. The economics are steering the conversation, and the evidence limitation should be named instead of hidden.
Knowing that does not automatically make the cheaper option wrong. It changes the questions you ask before accepting it.
The first generic arrived in 2025, and another approval followed in 2026
The FDA approved Xiromed's progesterone vaginal insert 100 mg as the first generic of Endometrin on September 19, 2025. Glenmark announced FDA approval of another 100 mg generic on April 9, 2026.
Those approvals may increase competition and access. They do not change the approved indication: progesterone support in assisted reproductive technology, not endometrial protection during menopausal HRT.
That distinction is exactly why this page separates three claims:
- FDA-approved product: yes.
- FDA-approved for vaginal use: yes.
- FDA-approved for menopause endometrial protection: no.
What to expect from insurance
Coverage is plan-specific. A plan may require prior authorization, diagnosis documentation, or a trial of a less expensive product before covering a brand-name insert or gel. Do not let a general article promise that your plan “will” impose step therapy or “will” grant an exception.
Use this script when the prescription is written:
“Please tell me the product, quantity, diagnosis or indication being submitted, whether prior authorization is required, and what the cash price is if coverage is denied.”
Then ask the pharmacy to quote the exact prescription before the office closes the loop. The number that matters is the one attached to your product, quantity, ZIP, and plan—not an affiliate page's imaginary monthly total.
What else can your prescriber consider if oral doesn't work?
Answer capsule: Oral intolerance has no single automatic substitute. Depending on uterus status, estrogen dose, bleeding history, contraindications, and access, a clinician may consider a supervised oral-equivalent vaginal regimen, a different progestogen, a 52 mg levonorgestrel IUD, or the FDA-approved conjugated-estrogens/bazedoxifene product Duavee. Each solves a different problem, and none should be treated as a casual one-for-one swap.
You have more options than “swallow it or quit.” Here are the real ones—and a fact that reframes the whole menu.
First, the fact that reframes the menu
A 2024 systematic review of progestogens for endometrial protection concluded that FDA endometrial-safety criteria were fulfilled for only some formulations, and that study quality varied.
Read that slowly. Not “all progestogens work the same.” Not “nothing works.” Product, route, schedule, estrogen exposure, duration, and outcome measurement all matter.
That's why “just switch to something else” is not a neutral move. Every alternative below sits somewhere different on the evidence-and-label map, and you're entitled to know where.
The 52 mg levonorgestrel IUD
Most “oral vs vaginal” articles never mention this, and for some women it is the option that changes the whole discussion.
A 52 mg levonorgestrel IUD delivers progestogen inside the uterus. May 2026 BMS guidance says it provides adequate endometrial protection with estrogen therapy; Mirena has a four-year HRT opposition license in the UK, and the BMS says evidence supports use for up to five years in HRT practice.
In the United States, Mirena's current label covers contraception for up to eight years and treatment of heavy menstrual bleeding for up to five years. It does not carry a U.S. indication for endometrial protection with menopausal estrogen. That use is off-label.
The honest trade: an insertion procedure, cramping or pain around placement for some women, irregular bleeding or spotting that may take months to settle, and no oral progesterone sedation or sleep effect.
The safety gap nobody publishes: BMS guidance says the lower-dose 13.5 mg and 19.5 mg hormonal IUDs lack evidence for HRT endometrial protection. If one of those is being used for contraception while systemic estrogen is added, the guidance recommends additional progestogen.
If you have a lower-dose or “small-frame” hormonal IUD and have been told it automatically covers your HRT, confirm the device and plan.
A different progestogen
“Progesterone intolerance” does not reliably predict how you will respond to every progestogen. Micronized progesterone, medroxyprogesterone acetate, norethisterone, and other progestogens differ in pharmacology, labels, side effects, and evidence.
Switching within the class is legitimate. It is also its own decision. We are not going to rank them inside an oral-versus-vaginal page without doing a separate, product-specific evidence review.
Duavee: an FDA-approved option that does not use a separate progestin
Duavee combines conjugated estrogens 0.45 mg with bazedoxifene 20 mg. The current U.S. label covers treatment of moderate to severe menopausal vasomotor symptoms and prevention of postmenopausal osteoporosis in women with a uterus. The bazedoxifene component reduces the risk of endometrial hyperplasia caused by the estrogen component.
This is not “estrogen plus a better progesterone.” It is a different FDA-approved regimen with its own boxed warning, contraindications, interactions, and limitations. The label says women taking Duavee should not add progestins, additional estrogens, or additional estrogen agonist/antagonists.
If progestogens as a class are the problem rather than swallowing one capsule, Duavee is a category worth naming out loud—not self-substituting.
Rechecking the estrogen side
The protection question is really an estrogen-to-progestogen balance question. Sometimes the right move is not a different progesterone route. It is confirming that the estrogen route and dose still fit the symptoms and risk profile, and that the two halves of the regimen were chosen together.
That is not us telling you to cut your estrogen. It is permission to ask whether the regimen was designed as a pair.
What is not a substitute—and this one matters most
Progesterone creams and gels applied to the skin should not be relied on for endometrial protection.
The 2016 systematic review concluded that transdermal micronized progesterone does not provide adequate endometrial protection. May 2026 BMS guidance says absorption through the skin is variable and is unlikely to provide sufficient opposition to estrogen.
The BMS guidance is equally direct about compounded products: it raises purity, potency, and safety concerns; says compounded bioidentical products have not been evaluated in randomized controlled trials; and does not recommend them when regulated alternatives are available.
To be precise about our own language: FDA-approved and compounded products are not equivalent. A compounded finished product has not undergone FDA premarket review for safety, effectiveness, quality, or labeling, and nothing on this page suggests it is safer, more natural, or interchangeable with an FDA-approved product.
Why this is the most consequential paragraph on the page: a woman who swaps an oral capsule for a skin cream to escape sedation may feel fewer systemic effects while losing reliable endometrial opposition. The lining may give no symptom that protection is inadequate.
Also not substitutes: over-the-counter progesterone creams, wild-yam products, supplements, or a progesterone blood level used as proof of endometrial protection. A serum number does not show what the uterine lining did over years. That's the whole reason this decision cannot be reduced to a lab value.
Will switching to vaginal progesterone cost you the sleep benefit?
Answer capsule: It might, but nobody has directly studied the exact before-and-after question well enough to promise it. Oral micronized progesterone has randomized and meta-analytic evidence for improving some sleep outcomes, and oral dosing creates the neuroactive exposure that can also cause grogginess. Vaginal products can produce different serum exposure, but the sleep effect after a route switch is unquantified.
This is the trade almost nobody warns women about, and it catches people out.
The 2022 hormone therapy position statement from The Menopause Society notes that oral micronized progesterone 300 mg nightly significantly decreased hot flashes and night sweats versus placebo and improved sleep. That finding concerns oral 300 mg progesterone as a studied regimen. It is not proof that the 100 mg capsule in your own HRT plan is a sleep medication, and it is not proof that vaginal dosing erases the effect.
The broader evidence is promising but uneven:
- A systematic review and meta-analysis of nine randomized controlled trials involving 388 participants found improvement in several sleep outcomes, predominantly in postmenopausal women, but results differed across outcomes and studies. Some trials used accompanying estradiol or enrolled women whose vasomotor symptoms were also improving.
- A randomized trial of oral micronized progesterone 300 mg nightly found a larger improvement in vasomotor symptoms than placebo in healthy early-postmenopausal women.
- Vaginal pharmacokinetic studies show that serum exposure can differ from systemic routes while uterine delivery remains substantial. They do not tell us how a woman who sleeps well on oral progesterone will sleep after switching.
So the honest sentence is not “you will lose the sleep benefit.” It is:
The same route change that may reduce sedation can also reduce a benefit you value, and the size of that trade has not been measured directly.
So who should stay exactly where they are?
We'd rather lose you here than watch you make a change you regret.
If oral progesterone is the reason you finally sleep, the morning effect is manageable, and the regimen is otherwise appropriate—staying on oral may be the cleaner choice. There is no prize for picking the more complicated route.
If that's you, the useful next question is not “How do I switch?” It is “Can the timing, estrogen-progestogen balance, or product be adjusted without giving up the part that works?”
If the morning fog is disabling, unsafe, or affecting driving, falls, work, or caregiving, that changes the decision. Tolerability is not a vanity concern. It is a reason to ask for another plan.
What do women actually report on each route?
Answer capsule: Published patient-reported data shows different burdens rather than a clean “fewer side effects” win. Vaginal products are associated with wetness, residue, leakage, incomplete-dissolution concerns, and local irritation. Oral progesterone is associated with sleepiness, dizziness, nausea, headache, and fatigue. Product choice determines which tradeoffs apply.
A note on why there are no customer quotes in this section. No woman can tell you from symptoms whether her uterine lining stayed healthy—that outcome is invisible without appropriate evaluation. A testimonial saying “I switched and feel so much better” can describe tolerability. It cannot prove endometrial protection.
On the vaginal route, published experience includes wetness, product residue, leakage, a sense that a tablet or gel has not fully dissolved, and itching or irritation. Gel products can leave residue that later comes out in small pieces. Those are practical burdens, not evidence that the dose failed.
On the oral route, reported experience includes sleepiness, dizziness, nausea, headache, bloating, breast tenderness, and fatigue. The current Prometrium label's placebo-controlled table helps separate the complaints with large treatment-placebo gaps from those reported nearly as often without active progesterone.
Does sex reduce vaginal progesterone absorption?
The evidence is product-specific and conflicting, so the draft's blanket answer had to go.
A small 2015 randomized study using vaginal progesterone gel in reproductive-age couples found lower progesterone levels in women after intercourse and measurable transfer to male partners. A newer crossover pilot published online in 2025 and in print in 2026, conducted during a hormone-replacement frozen-embryo-transfer cycle using vaginal progesterone suppositories, found no significant change in serum progesterone with protected or unprotected intercourse compared with abstinence.
Those studies used different products, populations, and designs. The defensible advice is not “sex always reduces absorption.” It is: ask about timing for the exact gel, insert, pessary, or capsule you were prescribed, and follow that product's instructions.
None of this establishes which route is better for you. It tells you what you're signing up for so the trade is at least a fair one.
Which route fits which situation?
Answer capsule: Oral micronized progesterone is usually the clearest starting point for a woman with a uterus on systemic estrogen who tolerates bedtime dosing, because it holds the relevant U.S. label and the deepest evidence. A clinician-directed vaginal regimen becomes a reasonable conversation when oral effects are genuinely disabling. Bleeding, higher-dose estrogen, or a complex uterine history calls for a plan—not an unsupervised route swap.
| Your situation | Likely starting direction | Why | What to verify |
|---|---|---|---|
| Uterus, systemic estrogen, oral is tolerable | Stay on oral unless another clinical reason exists | Best-established route, lowest verified package price, U.S.-labeled endometrial-hyperplasia indication | That the progesterone schedule was selected in relation to the estrogen route and dose |
| Uterus, systemic estrogen, disabling dizziness, grogginess, or mood effects | Ask about a supervised vaginal or alternative regimen | Tolerability is a legitimate reason to change the plan | Exact product, off-label rationale, dose, bleeding instructions, and follow-up |
| Oral progesterone is helping sleep and morning effects are manageable | Think twice before changing route | The sleep trade after switching is plausible but not quantified | Whether timing or another regimen adjustment can preserve the benefit |
| Higher-dose estrogen | Do not use a generic table as your prescription | BMS guidance says progestogen may need to increase, while also acknowledging the optimal dose data are limited | Prescriber rationale and monitoring plan |
| New, heavy, or persistent unscheduled bleeding | Evaluation before a route experiment | A route change can alter the pattern and obscure the signal | Timing, risk factors, examination, ultrasound, biopsy, or hysteroscopy as clinically indicated |
| Peanut allergy | Check the exact capsule and manufacturer | Brand Prometrium contains peanut oil; generic inactive ingredients vary | Current package insert or pharmacist confirmation |
| Prior endometrial ablation | Combined HRT principles still apply | The uterus remains; May 2026 BMS guidance recommends combined regimens | That the prescriber knows about the ablation |
| Only current low-dose vaginal estrogen, no systemic estrogen | Different question entirely | Low-dose local estrogen generally does not trigger the same progestogen requirement | That the product and dose truly are local low-dose therapy |
| Considering a compounded cream or gel | Ask which regulated option was ruled out and why | Compounded finished products are not FDA-approved; skin absorption is unreliable for protection | Formula, route, quality controls, evidence, and the reason regulated options do not fit |
| 13.5 mg or 19.5 mg hormonal IUD plus systemic estrogen | Do not assume the IUD alone is enough | May 2026 BMS guidance says evidence is lacking for these lower-dose devices | Device name, dose, and whether additional progestogen is needed |
| No reliable follow-up | Do not improvise an off-label route | Bleeding evaluation and regimen review are part of the safety plan | Access to a licensed prescriber and in-person evaluation when needed |
If X, ask Y
Short scripts. Use them almost word for word.
- If oral helps you sleep but wrecks your morning: “Can we adjust timing, product, or the wider regimen before changing route?”
- If you already started inserting the capsule: “What supports this exact product, dose, and schedule for my estrogen exposure, and what is our follow-up plan?”
- If a clinician says the routes are equivalent: “Which product, formulation, dose, schedule, and duration is that based on?”
- If a clinician says vaginal progesterone never protects the uterus: “Is that conclusion about my specific product and risk profile, or every vaginal formulation?”
- If you're bleeding: ask about evaluation before asking for a route change.
- If you're using a lower-dose hormonal IUD with systemic estrogen: “Does this exact device provide enough endometrial opposition, or do I need additional progestogen?”
- If price is driving the capsule-insertion recommendation: “Is this the clinically preferred product, the covered product, or simply the affordable product—and what evidence gap comes with that choice?”
When is this not a route question at all?
Answer capsule: Bleeding you did not expect needs assessment before you use a route change to “fix” it. May 2026 BMS guidance recommends investigation when unscheduled bleeding persists beyond four to six months despite regimen adjustments, when the amount or pattern is concerning, or when the clinical picture warrants it. Heavy bleeding or postmenopausal bleeding should not be self-triaged through a progesterone article.
Nothing in this section links anywhere that earns us anything. It shouldn't.
Reassurance first, because it's true and specific: unscheduled bleeding is common in the first months after starting or changing HRT, and BMS guidance says adjusting progestogen often controls it. The same guidance notes that endometrial-cancer risk among women with unscheduled bleeding on HRT is lower than among women with postmenopausal bleeding who are not taking HRT, especially when bleeding was absent before HRT began. Bleeding is not automatically bad news.
It does need looking at when: it persists beyond four to six months despite appropriate regimen adjustment, becomes heavy, starts after a previously settled pattern, occurs after a long bleed-free interval, or concerns you or your clinician. Depending on the situation, assessment may include transvaginal ultrasound, endometrial biopsy, hysteroscopy, or another examination.
Get urgent help for trouble breathing, chest pain, fainting, new one-sided weakness or other neurological symptoms, a severe allergic reaction, or thoughts of harming yourself. If you're in crisis in the United States, call or text 988.
And for the third time, because this is the one move on this page that can create preventable harm: do not quietly stop or reduce progesterone while continuing systemic estrogen if you have a uterus. Contact the prescriber promptly for a plan. If a medication reaction means you cannot take the next dose safely, seek urgent medication advice rather than inventing a replacement schedule.
When you need an examination, ultrasound, or biopsy, online HRT care may not be the right starting point. Your gynecologist, primary-care clinician, urgent service, or a local women's-health clinician can coordinate the in-person assessment.
What should you ask your prescriber before changing route?
Answer capsule: Bring the actual product, estrogen dose, progesterone schedule, and symptoms—not just the sentence “I don't tolerate it.” The conversation that works is specific: what is this regimen opposing, what exact vaginal product would replace it, what evidence supports the dose, what will it cost, and what bleeding or follow-up plan tells us to reassess?
Write these down. Take them in. You're allowed to.
- Does my progesterone or progestogen plan match my estrogen route and dose?
- What exact product am I taking—brand, generic manufacturer, strength, and inactive ingredients?
- Is the proposed use FDA-labeled, off-label, or compounded? Which part is off-label: product, route, dose, indication, or more than one?
- If we use vaginal progesterone, what exact product and dose are you choosing—and why does evidence for that product apply to my estrogen regimen?
- Are you prescribing a purpose-made vaginal product or asking me to insert an oral capsule?
- Are you assuming milligram-for-milligram equivalence between products or routes? What supports that?
- How long has this exact or closely comparable regimen been studied for endometrial outcomes?
- What should I do if my bleeding pattern changes?
- What follow-up is routine, and what finding would trigger ultrasound, biopsy, or another evaluation?
- What is the next option if this route does not solve the side effects?
- What will the exact prescription cost at my pharmacy before I commit?
- If price is driving the product choice, what evidence tradeoff am I accepting?
If the answers are specific enough that you could write them down afterward, you're in better hands. If they're vague, that's information too.
The one honest caution before you click anything
Midi Health is not covered by Medicare or Medicare-related plans, and it does not treat Medicaid or Medi-Cal patients—even on a self-pay basis. Its current pricing page says Medicare beneficiaries may be accepted as self-pay patients but cannot submit claims related to Midi visits, medications, or associated services.
If that's your coverage, Midi is not your route. Your existing gynecologist, primary-care clinician, a local menopause clinician, or an in-person cash-pay option is the more realistic starting point.
Midi currently says it is available in all 50 states, is in-network with most PPO plans, and charges $250 for an initial self-pay visit and $150 for continued-care visits. Coverage still varies by plan, and copays, deductibles, and coinsurance can apply. Those provider facts were rechecked on August 7, 2026.
Because this page is about a medication-route decision—not a “best provider” contest—the provider CTA stays after the evidence and disqualifications.
If your current prescriber will not engage with a documented route, dose, and monitoring discussion—and you fit Midi's coverage model—check whether a menopause-focused visit is available in your state and network.
→ Check Midi Health coverage and current self-pay pricing
Midi clinicians make their own treatment decisions. This page does not promise that a clinician will prescribe a particular route or product. The HRT Index may earn a commission if you book through an eligible link.
One more disqualification, and we mean it: if your gynecologist already knows your history and is willing to have this conversation, keep her. A clinician who knows your bleeding history, uterus history, imaging, and prior reactions may be worth more than a new platform. This page has probably already given you the questions you need.
If you need a separate cash-pay OB/GYN search, Sesame's women's-health marketplace lists online and, in select cities, in-person women's-health appointments with upfront cash pricing. Availability and the exact service still depend on location and clinician.
What else do women ask about oral vs vaginal progesterone?
Answer capsule: The practical questions are usually about cutting capsules, every-other-day dosing, leakage, sex, blood tests, bleeding, breast risk, and whether an oral capsule can be inserted. The answers below keep product, route, label status, and evidence separate so a simple FAQ does not undo the distinctions the rest of the page built.
Can I cut my progesterone capsule in half?
No. Prometrium and common micronized-progesterone capsules are oil-filled soft capsules, not scored tablets. Cutting one does not create a reliable half dose. If the dose needs to change, ask for a manufactured strength or a different prescribed regimen.
Can I take progesterone every other day instead of daily?
Do not create an every-other-day schedule on your own. The 2016 review suggested 100 mg vaginally every other day as a possible off-label regimen, but May 2026 BMS guidance moved to oral-equivalent doses and durations because evidence remains limited and the tested low-dose 45 mg regimen failed. A prescribed sequential schedule is different from casually skipping alternate doses.
Is Utrogestan the same as Prometrium?
Both are brands of micronized progesterone, but the finished products, inactive ingredients, strengths, labels, and country-specific licenses are not identical. Prometrium is a U.S. oral capsule whose current label contains peanut oil. UK products include oral capsules and purpose-made vaginal formulations or pessaries. Do not transfer a UK vaginal instruction to a U.S. Prometrium bottle without a prescriber.
Does vaginal progesterone leak?
It can. Vaginal gels, inserts, pessaries, and capsules can produce wetness, residue, or leakage. Gel residue may collect and later come out in small pieces. Leakage is a practical issue, not proof that all of the dose failed to absorb.
Does sex affect vaginal progesterone absorption?
There is no one answer for every product. A small 2015 study of vaginal gel found reduced progesterone levels after intercourse, while a newer fertility-cycle pilot using vaginal suppositories found no significant effect. Ask about timing for the exact product you use rather than applying one study to every formulation.
What time of day should I take oral progesterone?
The current Prometrium label directs bedtime dosing for the endometrial-hyperplasia regimen because transient dizziness and drowsiness can occur. Follow the instructions for your exact prescription and avoid driving or operating machinery until you know how it affects you.
Do I need a blood test to check my progesterone level?
A blood level can show circulating progesterone at one moment. It does not establish that the uterine lining has been adequately opposed over years. Do not let a serum number replace a product-specific dosing rationale, bleeding plan, or clinically indicated endometrial evaluation.
Will switching routes change my bleeding pattern?
It can. That is one reason not to use a route change as self-treatment for unexplained bleeding: you change the regimen while also changing the signal the clinician needs to interpret.
Is micronized progesterone safer for the breast than synthetic progestins?
Observational data suggest micronized progesterone may have a more favorable breast-risk profile than some synthetic progestins, but direct randomized breast-cancer outcome evidence is not complete. The PROBES randomized study is comparing micronized progesterone with norethisterone acetate; ClinicalTrials.gov lists estimated primary completion in September 2026, but no results were posted as of August 7, 2026. Anyone presenting the question as settled is ahead of the trial.
Can I stop progesterone once I'm fully through menopause?
Not simply because more time has passed. If you have a uterus and continue systemic estrogen, the endometrium still needs an adequate clinician-selected protection strategy. Menopause does not make the lining immune to estrogen.
My prescriber told me to insert my oral capsule. Is that normal?
It is a recognized off-label practice, especially when oral side effects are difficult. May 2026 BMS guidance says it can be considered exceptionally for oral intolerance, using oral-equivalent doses and durations, while also stating that absorption kinetics for oral capsules used vaginally have not been published. Ask why that product was chosen and what the follow-up plan is.
Is vaginal progesterone FDA-approved for menopause HRT?
No progesterone vaginal insert or gel in the United States is FDA-approved for endometrial protection during menopausal HRT. Endometrin and its generics are approved for assisted reproductive technology. Crinone 8% is approved for assisted reproductive technology, and Crinone 4% for secondary amenorrhea. A product can be FDA-approved and still be off-label for this use.
Is progesterone a controlled substance?
No. The current Prometrium label lists no DEA schedule. It is still a prescription medication, and route or dose changes belong with the prescriber.
What did The HRT Index actually verify?
Answer capsule: Under The HRT Index Verification Standard, we checked the current U.S. labels, May 2026 BMS guidance, the 2016 and 2021 evidence chain, generic approvals, displayed package prices, and Midi's current coverage terms. We did not test products, examine patients, or invent a monthly regimen where the off-label prescription quantity was unknown.
What we did. We read the current U.S. prescribing information for Prometrium, Endometrin or generic progesterone vaginal inserts, Crinone, Mirena, and Duavee. We recorded the product, route, indication, dose language, contraindications, and relevant adverse-reaction data rather than treating “progesterone” as one interchangeable item.
We read the British Menopause Society's May 2026 clinician tool on progestogens and endometrial protection in full. We traced its vaginal-dose discussion back to the 2016 systematic review and the 2021 ELITE endometrial analysis, then checked the disclosure statements behind the recommendation.
We captured the displayed package prices from GoodRx and Drugs.com on August 7, 2026. We did not convert off-label vaginal products into a fake monthly cost when the prescription quantity and menopause schedule had not been established.
We checked the FDA's first-generic record for Xiromed's progesterone vaginal insert and Glenmark's April 2026 approval announcement. We checked Midi's own coverage and self-pay page for state availability, PPO positioning, Medicaid, Medi-Cal, Medicare, and cash-visit pricing.
What we did not do. We did not test any product, examine a patient, or verify what a particular clinician will prescribe. We are not a clinic, and this page was not medically reviewed by a clinician. It is editorial research built from primary labels, professional guidance, peer-reviewed literature, and dated commercial-source checks.
Why there are no testimonials. No patient quote can establish whether a uterine lining remained protected. A testimonial belongs to tolerability, not efficacy or safety, and using one here would put persuasion where evidence belongs.
Why this page exists. Because “vaginal progesterone” is being treated online as one route with one dose, when it is actually several products with different strengths, indications, evidence, and prices. The 45 mg regimen that still circulates was tested later and found insufficient with oral estradiol 1 mg/day. That gap should not survive another copy-and-paste cycle.
Primary medical and regulatory sources
- Prometrium current U.S. prescribing information, DailyMed
- British Menopause Society: Progestogens and Endometrial Protection, May 2026
- Stute et al. 2016 systematic review
- Stute et al. 2024 systematic review
- Sriprasert et al. 2021 ELITE endometrial analysis
- Di Carlo et al. 2010 oral-versus-vaginal progesterone trial
- de Ziegler et al. 2000 Crinone menopause study
- The Menopause Society 2022 hormone therapy position statement
- Nolan et al. 2021 sleep systematic review and meta-analysis
- Crinone current U.S. label, DailyMed
- Mirena current U.S. label, DailyMed
- Duavee current U.S. label, DailyMed
- FDA 2025 first-generic approval record
- PROBES trial record, ClinicalTrials.gov
- Merriam et al. 2015 intercourse and vaginal progesterone gel study
- Ranisavljevic et al. SexVAP study
- Glenmark April 2026 progesterone vaginal-insert approval announcement
- Glenmark progesterone vaginal-insert label, DailyMed
Dated commercial-source checks
- GoodRx: progesterone capsules and inserts
- GoodRx: Endometrin
- GoodRx: Crinone
- Drugs.com: progesterone price guide
- Midi Health: pricing and insurance
- Sesame: women’s health marketplace
Byline: The HRT Index editorial team Last verified: August 2026 Next scheduled re-verification: November 2026 for labels, guidance, prices, and provider policies; after the PROBES study record posts results or changes status
Which HRT care path fits when the answer still depends?
Answer capsule: Product labels and route evidence can narrow the decision, but they cannot resolve your uterus history, bleeding pattern, estrogen exposure, insurance, state, or need for in-person care. Find My HRT Path turns those remaining variables into a care-route match and flags when telehealth should not be the starting point.
Take the free matching tool—about 90 seconds, no email needed.
It gives you a best-fit care route and two backups based on symptoms, uterus status, route preference, risk history, insurance or cash-pay needs, and state—and flags when online care is not the right starting point.
Related reading: Vaginal estrogen vs systemic estrogen · Find My HRT Path